Chester County News and Community Website
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) reported third-quarter 2025 financial results and outlined key progress across its oncology pipeline, including two drug candidates now moving toward clinical development …
Prelude Advances Two Novel Cancer Programs as Cash Runway Extends Into 2027 Read More
LANGHORNE, PA — NEXGEL, Inc. (Nasdaq: NXGL) reported third quarter 2025 results showing stable revenue and improved margins as the hydrogel manufacturer continued to advance both its contract manufacturing and …
Hydrogel Innovator NEXGEL Posts Steady Q3 as Margin Gains Offset Flat Revenue Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) reported third-quarter results and detailed an intensifying slate of clinical milestones as its QTORIN platform advances across four rare dermatologic diseases — …
Palvella Races Toward Key 2026 Readouts as Rare-Disease Pipeline Expands Rapidly Read More
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) reported third-quarter financial results and outlined steady progress across its upliFT-D gene therapy program, positioning the company for critical regulatory and clinical …
Passage Bio Pushes Toward Key 2026 Milestones as Gene Therapy Program Accelerates Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) reported third-quarter financial results and detailed a series of strategic and regulatory milestones that collectively secured more than $147 million …
Orchestra BioMed’s Big Cash Infusion Sets Stage for High-Stakes Cardiology Trials Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) reported third-quarter financial results and said it is preparing to submit a New Drug Application (NDA) for its lead candidate, lorundrostat, by …
Mineralys Nears Pivotal FDA Filing as Hypertension Drug Lorundrostat Advances Read More
NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) reported third-quarter financial results and outlined major clinical milestones that position the company for a pivotal two-year stretch focused on advancing …
ArriVent Maps Ambitious 2026 Oncology Push as Firmonertinib Program Gains Steam Read More
WILMINGTON, DE — The Chemours Company delivered a mixed third quarter, with strong refrigerant demand helping offset weakness across its titanium dioxide and advanced materials businesses.
Chemours Posts Solid Q3 as Refrigerants Surge and Other Segments Struggle Read More
WILMINGTON, DE — Qnity Electronics, Inc. (NYSE: Q), newly spun off from DuPont and now a standalone S&P 500 component, reported solid estimated third-quarter 2025 results, highlighted by double-digit sales …
Qnity Posts Strong Q3 Gains as Newly Independent Chip Supplier Raises 2025 Outlook Read More
WAYNE, PA — Trinseo (NYSE: TSE) reported another challenging quarter as soft global demand, pricing pressure in Europe, and lower equity income weighed heavily on results, pushing the specialty materials …
Trinseo’s Deeper Loss Spurs Aggressive Cuts as Demand Weakens Again Read More